key: cord-0932991-tawzpra7
authors: Giampietri, Linda; Belli, Elisabetta; Beatino, Maria Francesca; Giannoni, Sara; Palermo, Giovanni; Campese, Nicole; Tognoni, Gloria; Siciliano, Gabriele; Ceravolo, Roberto; De Luca, Ciro; Baldacci, Filippo
title: Fluid Biomarkers in Alzheimer’s Disease and Other Neurodegenerative Disorders: Toward Integrative Diagnostic Frameworks and Tailored Treatments
date: 2022-03-24
journal: Diagnostics (Basel)
DOI: 10.3390/diagnostics12040796
sha: e342472470c96320baf872e4934fa73319bd8d78
doc_id: 932991
cord_uid: tawzpra7

The diagnosis of neurodegenerative diseases (NDDs) represents an increasing social burden, with the unsolved issue of disease-modifying therapies (DMTs). The failure of clinical trials treating Alzheimer′s Disease (AD) so far highlighted the need for a different approach in drug design and patient selection. Identifying subjects in the prodromal or early symptomatic phase is critical to slow down neurodegeneration, but the implementation of screening programs with this aim will have an ethical and social aftermath. Novel minimally invasive candidate biomarkers (derived from blood, saliva, olfactory brush) or classical cerebrospinal fluid (CSF) biomarkers have been developed in research settings to stratify patients with NDDs. Misfolded protein accumulation, neuroinflammation, and synaptic loss are the pathophysiological hallmarks detected by these biomarkers to refine diagnosis, prognosis, and target engagement of drugs in clinical trials. We reviewed fluid biomarkers of NDDs, considering their potential role as screening, diagnostic, or prognostic tool, and their present-day use in clinical trials (phase II and III). A special focus will be dedicated to novel techniques for the detection of misfolded proteins. Eventually, an applicative diagnostic algorithm will be proposed to translate the research data in clinical practice and select prodromal or early patients to be enrolled in the appropriate DMTs trials for NDDs.

Neurodegenerative Diseases (NDDs) taken together represent a major burden for society. According to estimates, in 2020, Alzheimer s Disease (AD) and related dementias alone affected 13 million people in Europe and 59 million worldwide [1] . Now that Disease-Modifying Treatments (DMT) are approaching commercialization, healthcare structures will be asked to screen a large audience of possible beneficiaries and select and monitor the suitable subjects in a time-and cost-effective manner.

The question then is who and when? The failed AD clinical trials have taught us that pharmacological intervention even in moderate disease stages shuts the stable door after the horse has bolted [2] . Other than AD, pathophysiological processes in the whole NDDs spectrum start many years before the onset of clinical symptoms [3] [4] [5] [6] . The only possible 3.1. Blood Biomarkers 3.1.1. Aβ Peptides Among subjective memory complainers (SMC) and cognitively unimpaired (CU) subjects, the ratio of Aβ 1-42 and Aβ 1-40 determined in blood through the Simoa technique exhibits moderate to good accuracy in correctly predicting the amyloid status as assessed by PET or CSF [23] [24] [25] . Longitudinal studies carried out with Simoa report an ability of blood Aβ 1-42 and Aβ 1-42 /Aβ 1-40 to track AD clinical progression [23, 26] . In some investigations involving CU and clinical AD patients, blood Aβ 1-40 and Aβ 1-42 ratios assessed through immunoprecipitation coupled with mass-spectrometry (IP-MS) report good to optimal accuracy in differentiating amyloid-positive and negative participants [27, 28] . Interestingly, Aβ peptides misfolded species measured with an immunoinfrared sensor (iRS) identify amyloid-PET positivity with moderate accuracy and predict clinical AD diagnosis with optimal accuracy [29, 30] . The techniques applied in the studies above have been implemented to accurately quantify Aβ, as this peptide is prone to stick with non-specific molecules through hydrophobic interactions. Simoa represents a fully automated method relying on capturing antibody-coated microbeads that selectively target single Aβ proteins at subfemtomolar concentrations. In IP-MS, a tailored antibody-driven phase is associated with spectrometric analysis after a multi-step procedure aimed at minimizing matrix interference. At last, iRS is designed to quantify the amount of β-sheet enriched conformations of Aβ peptides compared to all Aβ species according to their relative frequency shift in the infrared, prior to a detection step through epitope-specific antibodies.

The levels of blood t-tau measured with Simoa in CU subjects are positively related to the risk of conversion to mild cognitive impairment (MCI) [31] . Moreover, a good accuracy of blood t-tau in predicting the tau-PET status among CU, MCI, and AD patients is reported, while this biomarker could poorly discriminate amyloid-positive from negative participants in analogous clinical populations [32, 33] . Novel insights come from the measurement of tau protein fragments, the full-length isoform being only a small part of the whole circulating protein pool. In this attempt, good to optimal accuracy was shown by t-tau species detected through N-terminal-directed antibodies in differentiating CU from MCI/AD patients [34] .

Mounting evidence supports the role of blood p-tau181 as a specific AD biomarker. In a large recent investigation, p-tau181 levels assessed in blood with an ECLIA-based method could identify both clinically-and neuropathologically-defined AD with good to excellent accuracy [35] (Table 1 ). Most interestingly, a similar performance is displayed by this marker in the discrimination of AD from frontotemporal lobar degeneration (FTLD) with either syndromic or autoptic identification [36, 37] (Table 1) . Additionally, plasma p-tau181 measured with Simoa differentiates AD from vascular dementia (VaD), Progressive Supranuclear Palsy/Corticobasal Syndrome (PSP/CBS), PD/Multiple System Atrophy (PD/MSA), and behavioral variant of FTD/primary progressive aphasia (bvFTD/PPA) with good to optimal accuracy [37] (Table 1) .

CSF p-tau217, measured with the traditional ELISA method, performs better than CSF p-tau181 in predicting the Aβ status as assessed by amyloid-PET and in discriminating AD from non-AD dementias [38] . Notably, when determined through N-terminal directed immunoassays, CSF p-tau181 and p-tau217 have a comparable accuracy in the distinction of AD from non-AD clinical pictures [39] . Recent data support the promising role of p-tau217 as a specific indicator of AD pathology when also detected in plasma [40, 41] (Table 1) . Some papers report a higher performance of CSF p-tau231 over p-tau181 in differentiating AD from CU subjects with either a clinical or autoptic confirmation [42] . Intriguingly, in a multicenter study, plasma p-tau231 determined with Simoa shows good to optimal accuracy in properly distinguishing clinical continuum of AD from CU and non-AD dementia subjects. Moreover, an earlier increase of p-tau231 plasma concentration compared to p-tau181 was observed through autoptic examination in AD patients [43] (Table 1) .

Although lacking in disease-specificity, blood Nfl is a robust biomarker of axonal degeneration across different NDDs [44] . In particular, Nfl detected in plasma or serum may be exploitable for both diagnostic and prognostic aims in AD [45] [46] [47] [48] [49] [50] (Table 1) . Of note, blood Nfl holds potential as a screening strategy in preclinical AD settings [50, 51] (Table 1) and was shown to predict the onset of disease in presymptomatic AD mutation carriers [52, 53] . In amyotrophic lateral sclerosis (ALS), significantly higher levels of blood Nfl compared to HC have been largely demonstrated [54] [55] [56] (Table 1) . Solid data suggest a feasible role of serum Nfl as a supportive tool in the diagnostic work-up of ALS and for disease staging as well [54] [55] [56] [57] [58] [59] (Table 1) . As opposed to AD, blood Nfl concentration seems to increase only in the symptomatic stage of ALS mutation carriers [60] . Moreover, Nfl levels in blood may be useful for selectively identifying FTD from psychiatric disorders which often display overlapping clinical pictures [61, 62] . Finally, this biomarker seems to be promising for the differential diagnosis between PD and atypical parkinsonisms such as PSP, CBD, and MSA [63] [64] [65] . Indeed, NfL measured in CSF of patients with pure autonomic failure (PAF)-predicted phenoconversion to MSA was absent in PD and DLB converters and in non-converters [66] .

Synaptic dysfunction and loss are considered early events in the AD pathogenesis and markers tracking these changes are regarded as promising in NDDs [67] .

Among proteins reflecting synaptic damage in NDDs, neurogranin (Ng) detected in CSF represents the most convincing biomarker, especially for AD [68] . Higher levels of CSF Ng have been extensively reported in AD patients compared to HC [69] [70] [71] (Table 1) . In several investigations, this protein shows a moderate accuracy in the discrimination between AD and HC [72] [73] [74] (Table 1) . Interestingly, the concentration of CSF Ng was higher in subjects with a typical amnestic phenotype of AD compared to atypical AD cases, suggesting a possible link with a selective hippocampal degeneration [75] . Robust evidence supports the role of CSF Ng as a staging and prognostic biomarker throughout the entire course of AD [69, 70, [76] [77] [78] . As for other biomarkers of neurodegeneration, a massive release is likely in the CSF and blood of CDJ patients.

Orther than Ng, CSF synaptosomal-associated protein-25 (SNAP-25), in particular its soluble form SNAP-25aa40, has shown good accuracy in discriminating AD from HCs and non-AD dementias [79] [80] [81] [82] . Similarly, synaptotagmin-1 and growth-associated protein 43 (GAP 43) CSF concentrations have been shown to be increased in AD-disorders, thus representing a potential biomarker of synaptic degeneration in AD [79, 83] . The biomarkers of synaptic dysfunction represent a promising tool for the biomarker-based diagnosis of NDDs; nevertheless, the possible contexts of use of CSF Ng and of the other emerging biomarkers in NDDs still deserve further exploration.

YKL-40 protein measured in CSF is emerging as a reliable indicator of neuroinflammation, a pathophysiological pathway common to the whole NDDs spectrum. CSF YKL-40 showed only moderate accuracy in the discrimination of AD from both HC and non-AD dementias (e.g., DLB and FTD) and in tracking the clinical progression of MCI to full-blown dementia due to AD [84, 85] . Several autoptic studies report an association between CSF YKL-40 and brain tau deposits across different tauopathies [86] [87] [88] , suggesting a link of YLK-40 and tau-driven neurodegenerative mechanisms. Additionally, some data show higher levels of CSF YKL-40 in ALS subjects compared to HC [89, 90] . Further studies are needed to better elucidate the role of CSF YKL-40 as a peripheral surrogate of neurodegeneration-related mechanisms in the pre-symptomatic/early stages of NDDs and its role as a monitoring biomarker for targeted anti-inflammatory therapies. 

Recently, the research for biomarkers derived from body fluids other than CSF and plasma has raised a great deal of interest. The object is to find the successful, less invasive combination of biomarkers, able to play a role in early diagnosis of NDD as a first-level screening, or to stratify high-risk populations using novel tools as protein misfolding amplification assays.

The well-known markers of amyloid cascade and axonal damage have been measured on saliva of AD patients, providing significant results, although not yet useful as clinical biomarkers. An analysis of salivary p-tau/t-tau ratio levels revealed a significant difference between AD subjects and HCs at S396 phosphorylation site, but with limited discriminatory accuracy [91] . Similar investigations were carried out analyzing salivary α-synuclein concentration in PD patients. Salivary total α-synuclein levels reported an excellent specificity but poor sensitivity to discriminate PD from HCs, while sensitivity increased for oligomeric α-synuclein alone or α-syn olig /α-syn total ratio [92] . Finally, the neuroprotective mediator heme oxygenase-1 measured in saliva reported a significantly higher concentration in early PD patients than control subjects [93] .

The olfactory epithelium (OE) is recently gaining attention in NDDs, potentially reflecting the pathological alterations within the brain. Tau, Aβ, and α-syn have been detected in the OE in patients with NDDs, but frequency, extent, and disease specificity of misfolded protein expression in olfactory mucosa is not yet determined [94] . In AD, neurological dysfunction in central and peripheral olfactory systems has been described. Previous studies found the spreading of soluble Aβ aggregates from peripheral to central olfactory centers even earlier than spatial memory dysfunction [95] . Recently, BSC4090 (a fluorescent ligand targeting neurofibrillary tangles) proved to be an interesting candidate proxy of AD pathology modification in olfactory mucosa biopsies. It fairly distinguished AD from HC (AUROC 0.778) with good accuracy [96] (Table 2) . RT-QuIC analyses for detection of α-syn in the olfactory mucosa of PD patients is reliable in both PD and prodromal PD patients [97] , and in DLB and prodromal DLB patients too [98] (Table 2) . According to a recent study, RT-QuIC resulted positive for α-syn deposition in the olfactory mucosa in 44.4% of REM sleep behavior disorder (RBD) patients [99] (Table 2 ).

Skin biopsies have been recently gaining attention for their potential diagnostic role in synucleinopathies. Deposits of p-α-syn have been reported in skin nerve fibers of PD patients but not in atypical parkinsonisms without synucleinopathy. Analysis of p-α-syn deposits in cutaneous nerve fibers are potential tools to predict phenoconversion in RBD patients. According to recent studies, RBD patients positive for p-α-syn depositions in skin biopsies progressed into PD or DLB during a 3-year-follow-up [100] (Table 3) . Interestingly, the percentage of p-α-syn-positive fibers in skin biopsies in RBD patients was associated with the probability to be diagnosed as prodromal PD [101] (Table 3) . Finally, RT-QuIC techniques proved 95% sensitivity and 100% specificity in detecting α-syn on skin biopsies in PD patients [102] (Table 3) . 

Traditional core biomarkers still remain poorly explored in urine. In AD, urinary concentration of exosomes-derived Aβ 1-42 might differentiate AD patients from HC [103] , but results are only preliminary. Separately, a large variety of metabolites demonstrated excellent discrimination between MCI and HC (for isoleucine, acetate, trimethylamine n-oxide, kynurenine, C2, SDMA, malonate, and 5-aminopentanoate), MCI and AD (for glucose, guanidinoacetate, urocanate, hippuric acid, cytosine, 2-and 3-hydroxyisovalerate, 2-ketoisovalerate, tryptophan, and malonate), AD and HC (for 2-hydroxyisovalerate, acetate, ethanolamine, pyridoxine, 2-hydroxybutyrate, and alpha-ketoisovalerate differentiating), and thus suggesting a possible utility for developing a test based on urine metabolomics in this regard [104] .

The α-syn concentration in urine was assessed in PD patients with traditional techniques, resulting in different oligomeric forms of α-syn between PD and HCs Fare clic o toccare qui per immettere il testo [105] . Lastly, further urinary metabolite, neopterin, differentiated ASL and HC with similar accuracy, and elevated concentration was associated to longer survival, but little worthwhile evidence is available [106] .

The retina has recently gained attention as a new source of potentially promising biomarkers. The thinning of the retinal ganglion cell inner plexiform layer has been associated with the gray matter volume obtained from MRI scans, suggesting that the retinal ganglion cells are potential markers of cerebral neurodegeneration [107] . In AD, elevated Aβ 42/40 peptides and p-tau in the retina have been reported [108] , with linear correlation between retinal and brain Aβ concentration [109] . Neuronal degeneration, retinal thinning, vascular abnormalities, and gliosis were detected in AD patients [110] . In regards to PD, decreased retinal vessel density and perfusion density were detected, as well as choroidal structural changes in PD patients [111] .

Originally developed for the in vivo detection of the prion protein, seeding amplifications assays are currently regarded as a reliable diagnostic tool for the diagnosis of prion disorders [112] . Recently, a growing body of evidence supports the role of these techniques for the in vivo assessment of protein misfolding and abnormal accumulation in NDDs [113, 114] .

Two main protein misfolding amplification assays have been developed so far, namely the RT-QuIC and the PMCA [115] (Figure 1 ). Both techniques enable the detection of small amounts of misfolded proteins by exploiting the ability of these species to further seed the misfolding of natively unfolded proteins [116] . The alternating cycles of nucleation, during which the misfolded species are amplified and aggregate into fibrils, and fragmentation in fact make quantifiable even small amounts of misfolded proteins [113, 116] . The main technical differences between RT-QuIC and PMCA are related to the fragmentation and quantification systems. In RT-QuIC, the fragmentation is obtained by mechanical shaking. The detection and quantification of the misfolded proteins occur in real-time thanks to a fluorescent dye, which emits a signal when interacting with fibrils, thus reflecting their concentration [117] . In PMCA, the fragmentation is obtained by means of a sonication process and the quantification of the reaction products does not take place real-time during the reaction, occurring instead at the end of the amplification phase. Traditional immunoassays like Western blotting are in fact coupled to the PMCA reaction to enable the quantification of misfolded species [113, 117] . Standardization of pre-analytical and analytical issues are still missing. Nevertheless, the high sensitivity and accuracy of protein amplification assays in detecting misfolded species, considered pivotal in NDDs, are promising for an in vivo biological definition of NDDs. means of a sonication process and the quantification of the reaction products does not take place real-time during the reaction, occurring instead at the end of the amplification phase. Traditional immunoassays like Western blotting are in fact coupled to the PMCA reaction to enable the quantification of misfolded species [113, 117] . Standardization of pre-analytical and analytical issues are still missing. Nevertheless, the high sensitivity and accuracy of protein amplification assays in detecting misfolded species, considered pivotal in NDDs, are promising for an in vivo biological definition of NDDs. 

The most robust evidence regarding the potential utility of protein misfolding amplification assays in NDDs comes from the field of α-synucleinopathies [113] .

Misfolded α-syn can in fact be detected by means of RT-QuIC in the CSF of patients with α-synucleinopathies, enabling the differentiation of this group of disorders from non-α-synuclein-related mimics [118] [119] [120] [121] . CSF α-syn PMCA is also reported to properly differentiate patients with α-synucleinopathies from other neurological conditions [122, 123] . Both assays seem to be potentially useful in the stratification of the spectrum of α-synucleinopathies, being able to differentiate Lewy-bodies-related disorders (LBD), namely PD and DLB, from other α-synucleinopathies like MSA [121, 123, 124] . Although a direct cross-platform comparison between RT-QuIC and PMCA is missing, preliminary data support a selective accuracy of RT-QuIC in detecting LBD and of PMCA in identifying MSA, thus supporting the notion that different α-synuclein strains may underly these disorders [125] . Intriguingly CSF protein misfolding amplification assays seem to represent potential tools for the stratification of prodromal α-synucleinopathies and for the screening of at high-risk patients. These include patients with RBD [121, 126, 127] (Table 4) , with PAF [121] , and carriers of mutations associated with genetic forms of PD (e.g., LRRK2 and GBA) [121, 128] . Preliminary results from longitudinal studies support the notion of an increased risk of phenoconversion to overt α-synucleinopathy in CSF α-syn-RT-QuICpositive patients compared to negative ones [127] . More recently, RT-QuIC was able to detect α-synuclein in the olfactory mucosa of patients with PD and RBD [97, 99] (Table 4) , opening new scenarios for a minimally invasive screening of patients with full-blown and prodromal α-synucleinopathies. The use of protein amplification assays for the detection of other misfolded proteins in CSF is still in its infancy. Nonetheless, preliminary results support a utility of CSF RT-QuIC in detecting 3R tau aggregates in Pick s Disease (PiD) [129] , 4R tau aggregates in PSP and CBD [130] , and TDP-43 inclusions in conditions belonging to the ALS-FTD spectrum [131] . As regards TDP-43, RT-QuIC was able to detect this protein also in pre-symptomatic mutation carriers [131] . At last, a single report suggested that CSF Aβ 1-42 PMCA assay could differentiate AD from non-AD neurological disorders [132] . To sum up, ultrasensitive protein amplification assays are now regarded as potential tools for the stratification of NDDs from their prodromal to their full-blown stages. They may open a window on key pathophysiological mechanisms and enable the in vivo tracking of dynamic time-trajectories of early neurodegenerative changes in NDDs. Although promising, these results deserve a more extensive validation and standardization, cross-platform comparisons, and further prospective evaluations. 

Clinical trial protocols for DMT of NDDs typically employ CSF fluid biomarkers as inclusion criteria or measure of study outcomes, and plasma biomarker as a measure of study outcomes. However, novel trials increasingly rely on plasma biomarkers, especially those investigating novel strategies. Here, we collected the most relevant information about biomarkers and clinical trials for AD and genetic forms of NDDs from Clinicaltrial.gov, updated at 31 May 2021.

The current role of biomarkers in AD clinical trial is to ensure appropriate patient selection, intercepting subjects in the Alzheimer s continuum [9] . The demonstration of targeted engagement seems to be crucial; however, less than 60% of current trials relies on it [133] . On the other hand, each of the proposed trials enrolled patients with evidence of amyloid pathology (PET or CSF detection) in different clinical stages of disease (prodromal, early symptomatic, mild AD). Indeed, core AD biomarkers are clinically established in tertiary centers for diagnosis and trial enrollment.

DMT strategies are mainly focused on amyloid or tau pathology, as the avoidance or clearance of misfolded protein deposition are still the most studied pharmacological approaches in AD and other NDDs. Furthermore, neuroinflammation is an emergent pathophysiological mechanism with possible alternatives of treatment compared to classical proteinopathy-based strategies.

The target of most DMT for AD remains to be amyloid pathology, despite the failure of many trials with anti-amyloid strategies.

Anti-amyloid engaged drugs are designed according to two main mechanisms: interference upstream of Aβ peptide generation, by enzymatic inhibition of γ-secretase or BACE1, which physiologically cleave APP into beta-amyloid peptides, or downstream of Aβ peptide generation, by promoting its removal in either mono/oligomeric, aggregated, or plaque form via active or passive immunization [134] .

None of the BACE or gamma-secretase inhibitors successfully concluded phase III trials, either due to the lack of significant clinical effect or an unfavorable benefit/risk profile [135, 136] . Among the "survivor" anti-β-amyloid drugs, there is one vaccine (ABvac40) and six monoclonal antibodies (Gantenerumab, Solanezumab, Lecanemab [BAN2401], Aducanumab, Donanemab, Crenezumab) now under phase II or III of clinical trials.

The ABvac40 phase I study did not consider CSF biomarkers as outcome measures. However, ABvac40 active immunization was measured with the presence of anti-Aβ 1-40 antibodies and plasma Aβ 1-40 levels [137] . The results from the phase II trial are still unavailable, nor the interim analysis presented at AAIC 2020 congress [138, 139] .

Gantenerumab, a fully human IgG1 antibody that binds a conformational epitope on Aβ fibrils, was initially tested at low-dose in two phase III studies, the SCarlet RoAD and Marguerite RoAD studies, and was able to significantly reduce in dose-dependent manner CSF p-tau and t-tau levels in prodromal AD patients [140] . This finding supported two trials (Graduate 1 and Graduate 2) currently active that consider CSF tau/Aβ 1-42 ratio as inclusion criteria; regarding established study outcome on CSF Aβ 1-42 , p-tau, t-tau, there are no results available.

Solanezumab is a humanized monoclonal IgG1 antibody that recognizes Aβ peptide just in the soluble monomeric form, and inhibits Aβ aggregation [141] . In trials designed for prodromal to moderate AD (EXPEDITION 1, 2, 3, PRO), CSF and plasma Aβ 1-40 and Aβ 1-42 biomarkers were used as outcome measures and the drug proved to be effective in target engagement with increased concentrations of both [141] [142] [143] . Though these trials were either terminated early or had failed clinical and functional endpoints, biomarker outcomes suggested the drug to be tested in cognitively healthy older adults with evidence of amyloid pathology (A4 study). In the ongoing trial (no results available), liquid biomarkers are among secondary study outcomes, as changes in CSF Aβ 1-42 , p-tau, t-tau levels from baseline [144] .

Lecanemab (BAN2401) is a humanized IgG1 monoclonal antibody that preferentially binds to soluble Aβ oligomers and protofibrils [145] . CSF Aβ 1-42 , p-tau, Ng, and NfL were evaluated as study outcomes as evident from recently published results of phase 2b study. The group treated with lecanemab 10 mg/kg monthly and 10 mg/kg biweekly, showed a substantial normalization of core AD and closely related biomarkers, with the increase in CSF Aβ 1-42 , reduction in CSF p-tau levels, and a trend regarding the reduction of CSF Ng and NfL [146] .

Finally, aducanumab, a fully human IgG1 monoclonal antibody that binds aggregated forms of Aβ [147] , received accelerated approval by the FDA on 7th June 2021. Only limited information is available about the results of the ENGAGE and EMERGE studies, two twin phase 3 studies on MCI and mild dementia due to AD. Evaluation of biomarker data shows a significant reduction in CSF p-tau but not t-tau levels in the treatment group [148] . An interim analysis of aducanumab clinical studies led to early termination for futility in March 2019, was redeemed after further post-hoc analysis with consequent FDA approval, and now is under open label phase III trial (EMBARK).

AD monogenic forms deserve a separate discussion. Solanezumab and gantenerumab were tested in a phase 2/3 trial for dementia prevention in pre-symptomatic and mildly symptomatic PSEN1/PSEN2/APP mutation carriers within the Dominantly Inherited Alzheimer Network Trials Unit (DIAN-TU) [149] , considering the DIAN Multivariate Cognitive Endpoint and fluid biomarkers as outcomes. Both drugs dosing were augmented four-to-five-fold during the trial due to evidence coming from trials on sporadic AD subjects. Results were presented at the AAIC 2020 conference. Solanezumab increased CSF Aβ 1-42 , but also NfL. Furthermore, the treatment group showed an accelerated decline in cognition to placebo [150] . Clinical worsening agreed with the increase of NfL as a liquid biomarker of neuronal degeneration. Despite showing a significant reduction of CSF t-tau, p-tau181, and NfL, Gantenerumab did not have the expected positive effect on cognition [151] .

Regarding tau pathology, therapeutic approaches comprise (a) active and passive immunization, (b) kinase inhibitors, meant to interfere with tau phosphorylation, (c) tau aggregation inhibitors, and (d) microtubule-stabilizing agents, that compensate p-tau loss of function [152] . Among the drugs now under phase II or III trials, there are two vaccines (AADvac1, ACI-35), five monoclonal antibodies (Semorinemab, Tilavonemab, Gosuranemab, Zagotenemab, and JNJ-63733657) and one aggregation inhibitor (TRx0237).

AADvac1 uses an epitope from amino acids 294 to 305 of the tau sequence, coupled to keyhole limpet hemocyanin [153] . CSF core AD biomarkers were optional as inclusion criteria for the phase II trial ADAMANT on mild AD, concluded in June 2019. The CFS levels of p-tau181 and p-tau217 and NfL were evaluated during the trial and the results were announced in a press release (9 September 2019) AADvac1 showed efficacy in inducing immunization, plus a significant slow-down of the expected increase of NfL in treated patients, and a trend in reduction of p-tau in the CSF [154] . Despite the promising results, no phase III trial has been announced yet.

ACI-35 is a vaccine directed against a synthetic tau fragment phosphorylated at sites pS396/pS404, with an improved version (ACI-35.030) currently in phase II clinical trial in MCI due to AD or Mild AD subjects. However, no fluid biomarker is included in the protocol as outcome measure [155] .

Semorinemab, a monoclonal antibody that targets all six isoforms of tau at the Nterminus, both monomeric and oligomeric, phosphorylated or not, was tested in two phase II trials on prodromal to mild AD (TAURIET, currently completed) and moderate AD (LAURIET, currently active, not recruiting). Both trials considered core AD and neuroinflammatory/neurodegenerative liquid biomarkers as outcome measures. Despite failing clinical and functional endpoints, during TAURIET, semorinemab reported lowered CSF t-tau and p-tau levels and increased tau in plasma, moreover it was influential on other CSF biomarkers like NfL, Ng, S100B, and sTREM1, as presented at International Conference on Alzheimer s and Parkinson s Diseases 2021 (unpublished results) [156] .

Other antibodies in phase II study do not consider liquid biomarkers in their protocol after patient inclusion except JNJ-63733657. For this antibody, CSF concentrations of total, free, and bound p217 tau fragments were measured. However, no results are available so far, except for the reduction in CSF free p217 tau of healthy subjects from a previous phase I study [157] .

Following epidemiological studies that reported a lower incidence of AD in NSAIDs long-term users [158] , an alleged role in prevention was given to NSAIDs, but prospective studies disproved this hypothesis [159, 160] . Nevertheless, inflammation is still believed to be one of the major factors implied in the AD pathophysiological process, and more targeted drugs are under development against it. Neuroinflammation is particularly oriented on the role of neuron-glial cell (both astrocytes and microglia) interactions, neural extracellular matrix (nECM), and signaling from the neurovascular unit [161] . Among those with the most definite target engagement, there are two monoclonal antibodies, AL002 and pepinemab.

AL002 binds the microglial receptor TREM2 and activates its signaling, thus modulating Aβ pathology through microglial scavenging [162, 163] . However, the phase II trial (INVOKE-2) does not use specified CSF and plasma biomarkers other than for enrollment [164] .

Pepinemab is a monoclonal antibody directed against semaphorin 4D, a glycoprotein released by neurons in response to stress, that binds a receptor on astrocytes and oligodendrocytes in CNS [165] , claimed to be upregulated in AD and HD subjects [166] . A phase II trial is now running with MCI to mild AD with serum and CSF neuroinflammatory cytokines dosage (IL-1, IL-2, IL-4, IL-5, IL-6, IL-10, IL-12, IL13, IFNγ, TNF-α, TGFβ), Tand B-lymphocytes' quantitation, plasma and CSF NfL, plasma and CSF Aβ 1-42 /Aβ 1-40 , CSF t-tau and p-tau, CSF YKL-40 concentrations as secondary outcomes (results not available) [167, 168] .

FTD is a heterogeneous NDDs, clinically presenting with behavioral disturbances or language disorders. Moreover, an overlap with ALS or parkinsonism (generally PSP or CBS) may occur [169] . ALS and FTD present a considerable clinical, pathological, and genetic overlap, and are currently considered as opposite poles of the same disease spectrum [170] . The TDP-43 accumulation is the pathological hallmark of ALS, whereas FTD patients show either TDP-43 or tau proteinopathy with a smaller number of cases with FUS pathology.

Genetic forms account for nearly 30% of FTD cases [169] . Three genes are mostly involved in autosomal dominant cases of FTD: progranulin (GRN), microtubule-associated protein tau (MAPT), and chromosome 9 open reading frame 72 (C9orf72) [169] . MAPT mutations generally exhibit full penetrance, while GRN and C9orf72 show age-related penetrance [171, 172] . Different genotypes have been associated with different clinical signs [173] and brain imaging patterns.

The identification of genetic mutations in FTD patients is paramount for the development of personalized treatments as well as the discovery of specific biomarkers.

Three biomarkers have recently gained attention: NfL, progranulin, and poly(G) dipeptide repeat proteins (DPRs) [169] . NfL levels reflect axonal damage is not specific for FTD but could be used as outcome measure for successful treatments in clinical trials [174] . Low concentration of progranulin in CSF or plasma is reported in GRN-mutated FTD, while C9orf72 mutation carriers show increased CSF poly(G) DPRs [169] .

Three new drugs are currently under investigation in phase II trials for GRN mutation carriers. AL001 is a recombinant human anti-human monoclonal IgG1 targeting sortilin (SORT1), which serves as a lysosomal trafficking receptor for progranulin. Results of phase II (INFRONT-2) and phase III (INFRONT-3) trials are not yet available. Data from phase I trial showed a dose-dependent increase of plasma and CSF progranulin levels in both symptomatic and asymptomatic FTD patients [175] . Change in blood-based biomarkers and optional CSF biomarkers (NfL and progranulin) will be determined in INFRONT-3 trial [176] .

Another therapeutic approach is based on gene therapy. PBFT02 and PR006 are adenoassociated viral vectors (AVV) carrying GRN, the gene encoding for human progranulin to patients cells. No data on biomarkers are available for PBFT02 [177] . The phase 2 trial PROCLAIM testing PR006 is currently ongoing and blood and CSF concentration of progranulin and NfL will be assessed. No preliminary results are still available [178] .

TDP-43 is present in inclusion in nearly 50% of FTD patients [179] characterized by hyperphosphorylation at Serine 409/410. Indeed, the protein casein-kinase 1δ (CK-1δ) inhibitors are promising targets, but no specific human studies or biomarkers have been proposed [180] .

ALS is characterized by high variability both in phenotype and genetic background. Around 10% of ALS patients have genetic mutations [181] . The most common are C9orf72 (40%), SOD1 (20%), FUS 1-5%, and TARBDP (1-5%) [182] . Abnormal aggregation of TDP-43 is the major pathological background (~95% of cases), followed by accumulation of misfolded SOD1 and FUS [183] .

The identification of reliable biomarkers with clinical utility in pharmacological trials is hampered by the multiple pathophysiological mechanisms underpinning ALS [184] . However, in genetic ALS, due to C9orf72 and SOD1 mutation carriers, poly(G) DPRs and SOD1 proteins assessed in CSF are encouraging. Importantly, NfL measured either in plasma or CSF is a promising fluid biomarker in ALS, reflecting the rate of disease progression and the involvement of upper motor neuron [184] . Thus, it could be used as surrogate of neurodegeneration progression in clinical trials.

Two antisense oligonucleotides are currently under investigation in genetic forms of ALS. BIIB067 (Tofersen) is an antisense drug that binds specifically to SOD1 mRNA, stopping SOD1 protein production [185] . Phase 3 trial is currently ongoing, and changes in CSF SOD1 concentration will be also evaluated. On the other hand, C9orf72 is targeted by BIIB078 in an ongoing Phase 1 trial [186] , but liquid biomarker are not assessed.

FUS is a DNA/RNA binding protein that can be associated with a variety of NDDs apart from ALS (i.e., FTD or polyglutamine diseases). FUS protein is physiologically located in the nucleus, while mutated proteins localize in the cytoplasm forming abnormal aggregates [187] . Mechanisms of the FUS-induced toxicity are debated, and no studies assessed FUS protein as fluid biomarker. A clinical trial recently started in ALS patients with FUS mutation. ION363 is a form of antisense therapy silencing mRNA coding for FUS protein, thus aiming to reduce its intracellular expression. CSF NfL and FUS concentrations will be measured as secondary outcome [188] .

The collected evidence suggests that the field of liquid biomarkers (as a liquid biopsy) is continuously evolving, facing the unmet needs of screening, early diagnosis, stratification, and prognosis of NDDs. The causative or core proteins of NDDs are paired with markers of cellular or synaptic damage and inflammation which can be revealed through blood, CSF, or alternative matrices assays. However, the discussed role of biomarkers is not prominent in many of the latest clinical trials for DMTs, which are more focused on clinical evaluation and neuroimaging, secondarily limiting the investigation of liquid biomarkers to CSF core proteins.

The gap between the development and clinical validation of liquid biomarkers is widened by their exclusion in clinical practice. Screening biomarkers, potentially useful to intercept patients in prodromal stages of NDDs are limited to research settings, not implemented in real-life screening campaigns. As a consequence, the enrollment in clinical trials of early-stage diseases is limited to symptomatic patients, except for the genetic forms.

Moreover, several technical aspects hinder the inclusion of biomarker assessment in clinical routine. Cross-platform evaluations for the wide-scale implementation of a standardized analyte-specific method, unbiased guidelines to homogenize cut-off values as well as pre-and post-analytical procedures, and the cost-effectiveness appraisal when considering the limited availability of highly innovative platforms (e.g., Simoa) are still unmet needs.

The feasibility of the screening approach is further limited by ethical issues since the NDDs have no effective treatment. A biomarker with a high negative predictive value could medicalize asymptomatic people that with further diagnostic assessments could receive an incurable diagnosis years before its actual onset. On the other hand, the evidence seems to point in the direction of an intervention to treat NDDs in their prodromal/preclinical phase. Preventive healthcare is widely accepted for an infective form of pandemic, as we are facing COVID-19. The NDDs, though representing a mounting issue for the rapidly escalating number of patients, are more difficult to approach with screening campaigns.

The accurate selection of candidate populations is the first step to consider proposing an algorithm for clinical screening, diagnosis, and prognosis. The elderly population seems to be the aim of the screening, considering aging as the major unmodifiable risk factor for NDDs, with the proposed target age of ≥65 years for asymptomatic people [189] .

The suggested age does not maximize the interception of asymptomatic patients, since 1 out of 10 people could have already developed the disease, but it could minimize the ethical issues [189] . Another unmodifiable risk factor to consider is familiarity, which could also increase the willingness of the patient to undergo screening tests, as commonly proposed for the genetic forms. The modifiable risk factors could guide the further selection, considering the metabolic and cardiovascular factors, such as metabolic syndrome, smoke habit, high body mass index in mid-life, type 2 diabetes mellitus, carotid atherosclerosis, hypertension, heart disease, and obstructive sleep apnea [190] [191] [192] . Following preliminary studies of validation, a clinical score could be made based on these factors to select the candidate population ( Figure 2) . Moreover, the medicalization of elders with at least two of the presented factors could be useful to treat the comorbidities, ameliorating their general health regardless of the putative NDDs.

A different approach regarding symptomatic patients can be considered, selecting subjective memory complainers [193] , patients with RBD [194] or PAF [121] , and psychiatric patients presenting atypical/late-onset depression, behavioral disturbances, or psychotic symptoms [61] (Figure 1 ). For these patients, the age and familiarity factors could be less strict as they would go through differential diagnoses for their disorders.

Candidate liquid biomarkers for the high-risk populations that can be validated in clinical practice; based on research data, there are blood levels of both NfL and p-tau. These biomarkers have been selected for their high negative predictive values and the feasibility of the sampling. NfL, indeed, lacking specificity, could be used as a screening marker of neuronal damage, being broadly elevated in NDDs also in prodromal stages [44, 52, 53] . The reported difference in NfL levels, with higher concentrations of plasma protein in PD compared to atypical parkinsonism, should not be taken into account in this phase but eventually evaluated based on the results of the diagnostic algorithm [63] [64] [65] .

The dosage of blood p-tau231 or p-tau181 through either ECLIA-based or Simoa methods could substantially distinguish the NfL positive population, respectively, in non-AD (NfL+, p-tau −) versus AD (NfL +, p-tau +) pathophysiology of the putative NDD [35, 43] .

The patients selected through these blood biomarkers go through a second level of the diagnostic algorithm. In particular, the AD group should be tested for CSF core proteins (Aβ 1-42 /Aβ 1-40 , p-tau/t-tau), functional imaging (FdG-and amyloid-PET), and diagnosed accordingly to specific criteria [21, 195] . In the AD group, the CSF dosage of Ng could be useful to monitor disease progression and distinguish the atypical phenotypes of AD [68, 75] . subjective memory complainers [193] , patients with RBD [194] or PAF [121] , and psychiatric patients presenting atypical/late-onset depression, behavioral disturbances, or psychotic symptoms [61] (Figure 1 ). For these patients, the age and familiarity factors could be less strict as they would go through differential diagnoses for their disorders. Candidate liquid biomarkers for the high-risk populations that can be validated in clinical practice; based on research data, there are blood levels of both NfL and p-tau. These biomarkers have been selected for their high negative predictive values and the feasibility of the sampling. NfL, indeed, lacking specificity, could be used as a screening marker of neuronal damage, being broadly elevated in NDDs also in prodromal stages [44, 52, 53] . The reported difference in NfL levels, with higher concentrations of plasma protein in PD compared to atypical parkinsonism, should not be taken into account in this phase but eventually evaluated based on the results of the diagnostic algorithm [63] [64] [65] . Flowchart representation of the proposed diagnostic algorithm, starting with a high-risk population for NDDs at a preclinical level. The first level of screening is constituted by blood sampling and NFL/p-tau dosage. The screened population will undergo specific diagnostic assessment for suspected AD or be further stratified for α-synucleinopathy through misfolded protein amplification assays. The final goal is to ameliorate the patient quality of life, treat their comorbidities and enroll them into tailored clinical trials. PAF: pure autonomic failure; RBD: rapid eye movement sleep behavior disorder; OSAS: obstructive sleep apnea syndrome; NDDs: neurodegenerative diseases: NFL: neurofilaments RT-QuIC: real-time quaking Induced conversion; PMCA: protein misfolding cyclic amplification; LDB: Lewy body diseases; MSA: multiple system atrophy; CSF: cerebrospinal fluid AD: Alzheimer s disease.

The non-AD group can be further studied through the CSF quantification of αsynuclein by means of RT-QuIC and PMCA to differentiate NDDs in α-synucleinopathies and other NDDs. The two novel techniques to measure α-synuclein could be useful also to stratify the α-synucleinopathies in LBD or MSA [121, 122] . Eventually, the remaining putative NDDs should undergo conventional diagnostic tests, neuroimaging, and genetic testing (e.g., C9orf72, MAPT, GRN, SOD-1). Progranulin and poly(GP) DPRs CSF levels could be used, respectively, in GRN and C9orf72 mutations to follow disease progression during clinical trials [169] .

The alternative matrices for screening or diagnosis or to monitor disease progression are not ready to be applied in the present algorithm; however, RT-QuIC could be applied to skin biopsies to detect α-synuclein in PD patients [102] .

The selected patients can be enrolled in specific clinical trials of DMTs, in the early or prodromal stages of the diagnosed disease, potentially ameliorating the drug targeted intervention in phases of the NDDs characterized by higher resilience of the CNS.

Asymptomatic subjects, fully aware and cognitively unimpaired, who decide to undergo this kind of diagnostic work-up should receive adequate counselling before. The diagnosis of a specific pre-symptomatic disease implies the right to know (or to know not), planning, access to DMT trials, but it exposes these subjects to overdiagnosis and overtreatment among the other risks [196] . Further concerns come from those who enter the screening process but fail to meet any of the specific neuropathologies (NfL +, negative all the rest), leaving the subject to deal with an increased risk of a non-further-specified NDD. Future technologies and novel biomarkers implementation will increase the accuracy of screening procedures and progressively reduce the percentage of subjects that fall in this last group. The biomarker of accessible body fluids as blood (first level) and more invasive but easily performable procedures as lumbar puncture for CSF collection (second level), together with emerging matrices, could facilitate the clinical selection of patients. More limited evidence is collected about prognostic and monitoring validity of the available markers. A dosage of liquid biomarker is affordable both in terms of materials and human resources despite some technical drawbacks that are amendable. Moreover, compared to functional and traditional imaging, biomarkers can be reassessed coherently at low cost, are more sensitive to molecular changes, do not require the administration of tracers or contrast enhancers, and could furnish additional information about disease pathophysiology. The proposed algorithm is based on the state-of-the-art research data on liquid biomarkers; more evidence is needed to validate them in clinical practice. Eventually, the flowchart could be improved with emergent neuroinflammatory mechanisms [161, 197] and other biomarkers that account for synaptic loss [68] or more specific for primary tauopathies [129] [130] [131] , but further investigations are needed to translate them into clinical applications. Finally, we guess a combined use of multiple biomarkers (Table 5) is mandatory to precisely stratify NDDs depicting the essential characteristic of neurodegeneration such as neurodegeneration tout court (e.g., NFL), specific AD (p-tau and β-amyloid 40-42 peptides), and synuclein-related neurodegenerations (α-syn), and synaptic dysfunction (e.g., Ng). This awaits progress for reliable indicators of neuroinflammation, TDP-43, and 3R/4R pathologies as well. Institutional Review Board Statement: Not applicable.

Data Availability Statement: Not applicable.

The authors declare no conflict of interest.

People with Dementia Worldwide: An Update to the Estimates in the World Alzheimer Report

Why do trials for Alzheimer's disease drugs keep failing? A discontinued drug perspective for 2010-2015

Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade

The prodromal phase of sporadic Parkinson's disease: Does it exist and if so how long is it?

When do a-Synucleinopathies start? An epidemiological timeline a review

Early pathogenesis in the adult-onset neurodegenerative disease amyotrophic lateral sclerosis

Accuracy of the clinical diagnosis of Alzheimer disease at National Institute on Aging Alzheimer Disease Centers

Accuracy of clinical diagnosis of dementia with Lewy bodies: A systematic review and meta-analysis

Toward a biological definition of Alzheimer's disease. Alzheimer's Dement

The diagnosis of mild cognitive impairment due to Alzheimer's disease: Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimer's Dement

Toward defining the preclinical stages of Alzheimer's disease: Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimer's Dement

Update of the MDS research criteria for prodromal Parkinson's disease

MDS research criteria for prodromal Parkinson's disease

Research criteria for the diagnosis of prodromal dementia with Lewy bodies

The path to biomarker-based diagnostic criteria for the spectrum of neurodegenerative diseases

Non-Alzheimer neurodegenerative pathologies and their combinations are more frequent than commonly believed in the elderly brain: A community-based autopsy series

Ultrasensitive techniques and protein misfolding amplification assays for biomarker-guided reconceptualization of Alzheimer's and other neurodegenerative diseases

Neurodegenerative disease concomitant proteinopathies are prevalent, age-related and APOE4-associated

Association of TDP-43 proteinopathy, cerebral amyloid angiopathy, and Lewy bodies with cognitive impairment in individuals with or without Alzheimer's disease neuropathology

The diagnosis of dementia due to Alzheimer's disease: Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimer's Dement

Advancing research diagnostic criteria for Alzheimer's disease: The IWG-2 criteria

Biomarkers and diagnostic guidelines for sporadic Creutzfeldt-Jakob disease

Flier, W.M. Plasma Amyloid as Prescreener for the Earliest Alzheimer Pathological Changes

Plasma amyloid β 40/42 ratio predicts cerebral amyloidosis in cognitively normal individuals at risk for Alzheimer's disease. Alzheimer's Dement

Ultrasensitive Detection of Plasma Amyloid-β as a Biomarker for Cognitively Normal Elderly Individuals at Risk of Alzheimer's Disease

Plasma tau, neurofilament light chain and amyloid-β levels and risk of dementia; a population-based cohort study

Amyloid β concentrations and stable isotope labeling kinetics of human plasma specific to central nervous system amyloidosis

High performance plasma amyloid-β biomarkers for Alzheimer's disease

Amyloid blood biomarker detects Alzheimer's disease

Amyloid-β misfolding as a plasma biomarker indicates risk for future clinical Alzheimer's disease in individuals with subjective cognitive decline

Association of Plasma Total Tau Level With Cognitive Decline and Risk of Mild Cognitive Impairment or Dementia in the Mayo Clinic Study on Aging

Plasma tau/amyloid-β1-42 ratio predicts brain tau deposition and neurodegeneration in Alzheimer's disease

Plasma phospho-tau181 increases with Alzheimer's disease clinical severity and is associated with tau-and amyloid-positron emission tomography

Learnings about the complexity of extracellular tau aid development of a blood-based screen for Alzheimer's disease. Alzheimer's Dement

Plasma P-tau181 in Alzheimer's disease: Relationship to other biomarkers, differential diagnosis, neuropathology and longitudinal progression to Alzheimer's dementia

Diagnostic value of plasma phosphorylated tau181 in Alzheimer's disease and frontotemporal lobar degeneration

Blood phosphorylated tau 181 as a biomarker for Alzheimer's disease: A diagnostic performance and prediction modelling study using data from four prospective cohorts

Cerebrospinal fluid p-tau217 performs better than p-tau181 as a biomarker of Alzheimer's disease

Head-to-head comparison of clinical performance of CSF phospho-tau T181 and T217 biomarkers for Alzheimer's disease diagnosis

Blood plasma phosphorylated-tau isoforms track CNS change in Alzheimer's disease

Discriminative Accuracy of Plasma Phospho-tau217 for Alzheimer Disease vs Other Neurodegenerative Disorders

Greater Specificity for Cerebrospinal Fluid P-tau231 over P-tau181 in the Differentiation of Healthy Controls from Alzheimer's Disease

Plasma p-tau231: A new biomarker for incipient Alzheimer's disease pathology

Different Clinical Contexts of Use of Blood Neurofilament Light Chain Protein in the Spectrum of Neurodegenerative Diseases

Plasma neurofilament light as a potential biomarker of neurodegeneration in Alzheimer's disease

Association between Longitudinal Plasma Neurofilament Light and Neurodegeneration in Patients with Alzheimer Disease

Association between cerebrospinal fluid and plasma neurodegeneration biomarkers with brain atrophy in Alzheimer's disease

Neurofilament Light Chain in Cerebrospinal Fluid and Blood as a Biomarker for Neurodegenerative Diseases: A Systematic Review and Meta-Analysis

Increased plasma neurofilament light chain concentration correlates with severity of post-mortem neurofibrillary tangle pathology and neurodegeneration

Alzheimer's Disease Neuroimaging Initiative. Association of Plasma Neurofilament Light With Neurodegeneration in Patients with Alzheimer Disease

Neurofilament light chain plasma concentration predicts neurodegeneration and clinical progression in nondemented elderly adults

Serum neurofilament dynamics predicts neurodegeneration and clinical progression in presymptomatic Alzheimer's disease

Serum neurofilament light in familial Alzheimer disease

Serum neurofilament light chain levels as a marker of upper motor neuron degeneration in patients with Amyotrophic Lateral Sclerosis

Neurofilament as a blood marker for diagnosis and monitoring of primary progressive aphasias

Diagnostic and Prognostic Biomarkers in Amyotrophic Lateral Sclerosis

Neurofilament light chain in serum for the diagnosis of amyotrophic lateral sclerosis

Serum neurofilament light chain at time of diagnosis is an independent prognostic factor of survival in amyotrophic lateral sclerosis

Neurofilament markers for ALS correlate with extent of upper and lower motor neuron disease

Neurofilament levels as biomarkers in asymptomatic and symptomatic familial amyotrophic lateral sclerosis

Neurofilament light chain as a blood biomarker to differentiate psychiatric disorders from behavioural variant frontotemporal dementia

Serum neurofilament light chain is a discriminative biomarker between frontotemporal lobar degeneration and primary psychiatric disorders

CSF and blood biomarkers for Parkinson's disease

Serum NFL discriminates Parkinson disease from atypical parkinsonisms

Alpha-Synuclein Oligomers and Neurofilament Light Chain Predict Phenoconversion of Pure Autonomic Failure

Current state of Alzheimer's fluid biomarkers

The role of synaptic biomarkers in the spectrum of neurodegenerative diseases

Cerebrospinal fluid levels of the synaptic protein neurogranin correlates with cognitive decline in prodromal Alzheimer's disease. Alzheimer's Dement

Neurogranin as a Cerebrospinal Fluid Biomarker for Synaptic Loss in Symptomatic Alzheimer Disease

CSF neurogranin as a neuronal damage marker in CJD: A comparative study with AD

Diagnostic and Prognostic Utility of the Synaptic Marker Neurogranin in Alzheimer Disease

Cerebrospinal fluid tau, neurogranin, and neurofilament light in Alzheimer's disease

Cerebrospinal Fluid Neurogranin as a Biomarker of Neurodegenerative Diseases: A Cross-Sectional Study

CSF neurogranin or tau distinguish typical and atypical Alzheimer disease

Cerebrospinal fluid neurogranin: Relation to cognition and neurodegeneration in Alzheimer's disease

Neurogranin as a predictor of memory and executive function decline in MCI patients

Cerebrospinal fluid biomarkers of neurodegeneration, synaptic integrity, and astroglial activation across the clinical Alzheimer's disease spectrum

Dissection of synaptic pathways through the CSF biomarkers for predicting Alzheimer disease

SNAP-25 is a promising novel cerebrospinal fluid biomarker for synapse degeneration in Alzheimer's disease

Cerebrospinal fluid synaptosomalassociated protein 25 is a key player in synaptic degeneration in mild cognitive impairment and Alzheimer's disease

A Novel ELISA for the Measurement of Cerebrospinal Fluid SNAP-25 in Patients with Alzheimer's Disease

The pre-synaptic vesicle protein synaptotagmin is a novel biomarker for Alzheimer's disease. Alzheimer's Res

Fluid Candidate Biomarkers for Alzheimer's Disease: A Precision Medicine Approach

The neuroinflammatory biomarker YKL-40 for neurodegenerative diseases: Advances in development

Diagnostic function of the neuroinflammatory biomarker YKL-40 in Alzheimer's disease and other neurodegenerative diseases. Expert Rev

YKL-40 (Chitinase 3-like I) is expressed in a subset of astrocytes in Alzheimer's disease and other tauopathies

YKL-40, and neurofilament light in frontotemporal lobar degeneration

Different neuroinflammatory profile in amyotrophic lateral sclerosis and frontotemporal dementia is linked to the clinical phase

Neurofilament light chain and tau concentrations are markedly increased in the serum of patients with sporadic Creutzfeldt-Jakob disease, and tau correlates with rate of disease progression

Development and validation of a salivary tau biomarker in Alzheimer's disease. Alzheimer's Dement

Feng, T. α-Synuclein in salivary extracellular vesicles as a potential biomarker of Parkinson's disease

Evaluation of salivary heme oxygenase-1 as a potential biomarker of early Parkinson's disease

Olfactory epithelium amyloid-β and paired helical filament-tau pathology in Alzheimer disease

Amyloid-β Deposition and Olfactory Dysfunction in an Alzheimer's Disease Model

Evaluation of the methoxy-X04 derivative BSC4090 for diagnosis of prodromal and early Alzheimer's disease from bioptic olfactory mucosa

Efficient RT-QuIC seeding activity for α-synuclein in olfactory mucosa samples of patients with Parkinson's disease and multiple system atrophy

Alpha-synuclein seeds in olfactory mucosa and cerebrospinal fluid of patients with dementia with Lewy bodies

Alpha-synuclein seeds in olfactory mucosa of patients with isolated REM sleep behaviour disorder

Immunohistochemical Detection of Synuclein Pathology in Skin in Idiopathic Rapid Eye Movement Sleep Behavior Disorder and Parkinsonism

Dermal phospho-alpha-synuclein deposits confirm REM sleep behaviour disorder as prodromal Parkinson's disease

Skin α-Synuclein Aggregation Seeding Activity as a Novel Biomarker for Parkinson Disease

A Pilot Study of Urinary Exosomes in Alzheimer's Disease

Targeted Metabolic Profiling of Urine Highlights a Potential Biomarker Panel for the Diagnosis of Alzheimer's Disease and Mild Cognitive Impairment: A Pilot Study

Analysis of α-synuclein levels related to LRRK2 kinase activity: From substantia nigra to urine of patients with Parkinson's disease

Urinary neopterin, a new marker of the neuroinflammatory status in amyotrophic lateral sclerosis

Ocular indicators of Alzheimer's: Exploring disease in the retina

Alzheimer's Retinopathy: Seeing Disease in the Eyes

Advances in retina imaging as potential biomarkers for early diagnosis of Alzheimer's disease

Characterization of Retinal Microvascular and Choroidal Structural Changes in Parkinson Disease

Advanced tests for early and accurate diagnosis of Creutzfeldt-Jakob disease

Are We Ready for Detecting α-Synuclein Prone to Aggregation in Patients? The Case of "Protein-Misfolding Cyclic Amplification" and "Real-Time Quaking-Induced Conversion

Towards an improved early diagnosis of neurodegenerative diseases: The emerging role of in vitro conversion assays for protein amyloids

Proteopathic Seed Amplification Assays for Neurodegenerative Disorders

Prion protein amplification techniques

Cell-free amplification of prions: Where do we stand? Prog

α-Synuclein real-time quaking-induced conversion in the cerebrospinal fluid of uncertain cases of parkinsonism

α-Synuclein RT-QuIC assay in cerebrospinal fluid of patients with dementia with Lewy bodies

Rapid and ultra-sensitive quantitation of disease-associated α-synuclein seeds in brain and cerebrospinal fluid by αSyn RT-QuIC

Ultrasensitive RT-QuIC assay with high sensitivity and specificity for Lewy body-associated synucleinopathies

Discriminating α-synuclein strains in Parkinson's disease and multiple system atrophy

Development of a Biochemical Diagnosis of Parkinson Disease by Detection of α-Synuclein Misfolded Aggregates in Cerebrospinal Fluid

Alpha-Synuclein Oligomers and Neurofilament Light Chain in Spinal Fluid Differentiate Multiple System Atrophy from Lewy Body Synucleinopathies

Distinct α-Synuclein strains and implications for heterogeneity among α-Synucleinopathies

Alpha-synuclein RT-QuIC in the CSF of patients with alpha-synucleinopathies

Detection of α-synuclein in CSF by RT-QuIC in patients with isolated rapid-eye-movement sleep behaviour disorder: A longitudinal observational study

Alpha-synuclein RT-QuIC in cerebrospinal fluid of LRRK 2-linked Parkinson's disease

Ultrasensitive and selective detection of 3-repeat tau seeding activity in Pick disease brain and cerebrospinal fluid

4-Repeat tau seeds and templating subtypes as brain and CSF biomarkers of frontotemporal lobar degeneration

TDP-43 real-time quaking induced conversion reaction optimization and detection of seeding activity in CSF of amyotrophic lateral sclerosis and frontotemporal dementia patients

Detection of Misfolded Aβ Oligomers for Sensitive Biochemical Diagnosis of Alzheimer's Disease

Use of biomarkers in ongoing research protocols on alzheimer's disease

A critical appraisal of amyloid-β-targeting therapies for Alzheimer disease

Small-molecule BACE1 inhibitors: A patent literature review

Secretase inhibitors and modulators

Tolerability and Immunogenicity of an Active Anti-Aβ40 Vaccine (ABvac40) in Patients with Alzheimer's Disease: A Randomised, Double-Blind

Safety, tolerability and immunogenicity of an active anti-Aβ40 vaccine (ABvac40) in patients with amnestic mild cognitive impairment (A-MCI) or very mild alzheimer's disease (VM-AD): A randomized, double-blind

Safety and Immunogenicity of Repeated Doses of ABvac40 in Patients with A-MCI or Vm-AD

A phase III randomized trial of gantenerumab in prodromal Alzheimer's disease. Alzheimer's Res

Solanezumab for the treatment of mild-to-moderate Alzheimers disease

Phase 3 Trials of Solanezumab for Mild-to-Moderate Alzheimer's Disease

Trial of Solanezumab for Mild Dementia Due to Alzheimer's Disease

Clinical Trial of Solanezumab for Older Individuals Who May Be at Risk for Memory Loss

The murine Version of BAN2401 (mAb158) selectively reduces amyloid-β protofibrils in brain and cerebrospinal fluid of tg-ArcSwe Mice

A randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer's disease with lecanemab, an anti-Aβ protofibril antibody

Structural and kinetic basis for the selectivity of aducanumab for aggregated forms of amyloid-β

EMERGE and ENGAGE topline results: Phase 3 studies of aducanumab in early Alzheimer's disease

Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia. A Study of Potential Disease Modifying Treatments in Individuals at Risk for or with a Type of Early Onset Alzheimer's Disease Caused by a Genetic Mutation

Learning from the Past: A Review of Clinical Trials Targeting Amyloid, Tau and Neuroinflammation in Alzheimer's Disease

Axon Announces Positive Results from Phase II ADAMANT Trial for AADvac1 in Alzheimer's Disease

A Study to Evaluate the Safety, Tolerability and Immunogenicity of Tau Targeted Vaccines in Participants with Early Alzheimer's Disease

Mid-Domain Ones Push to the Fore|ALZFORUM

P1-052: A Single Ascending Dose Study To Evaluate The Safety, Tolerability, Pharmacokinetics, And Pharmacodynamics Of The Anti-Phospho-Tau Antibody JNJ-63733657 In Healthy Subjects. Alzheimer's Dement

The potential of anti-inflammatory drugs for the treatment of Alzheimer's disease

Aspirin and other non-steroidal anti-inflammatory drugs for the prevention of dementia

Aspirin, steroidal and non-steroidal anti-inflammatory drugs for the treatment of Alzheimer's disease. Cochrane Database Syst

Neurons, glia, extracellular matrix and neurovascular unit: A systems biology approach to the complexity of synaptic plasticity in health and disease

Anti-human TREM2 induces microglia proliferation and reduces pathology in an Alzheimer's disease model

A Path Toward Precision Medicine for Neuroinflammatory Mechanisms in Alzheimer's Disease. Front

A Phase 2 Study to Evaluate Efficacy and Safety of AL002 in Participants with Early Alzheimer's Disease

Generation and preclinical characterization of an antibody specific for SEMA4D

Evidence that semaphorin 4D is upregulated in neurons in Huntington's and Alzheimer's diseases: Effects of a SEMA4D blocking antibody on FDG-PET in a clinical trial, and treatment rationale for its use in AD

SEMA4D Blockade Safety and Brain Metabolic Activity in Alzheimer's Disease (AD)

An update on genetic frontotemporal dementia

Moving toward Patient-Tailored Treatment in ALS and FTD: The Potential of Genomic Assessment as a Tool for Biological Discovery and Trial Recruitment

Mutations in progranulin are a major cause of ubiquitin-positive frontotemporal lobar degeneration

Age-related penetrance of the C9orf72 repeat expansion

Genotype-phenotype links in frontotemporal lobar degeneration

Neurofilaments and tau in CSF in an infant with SMA type 1 treated with nusinersen

Alector Announces Data from On-Going Phase 1b Trial Demonstrating That AL001 Reverses Progranulin Deficiency in Frontotemporal Dementia Patients

A Phase 3 Study to Evaluate Efficacy and Safety of AL001 in Frontotemporal Dementia (INFRONT-3)

A Study of PBFT02 in Patients with Frontotemporal Dementia and Progranulin Mutations (FTD-GRN). Available online

Phase 1/2 Clinical Trial of PR006 in Patients with Frontotemporal Dementia with Progranulin Mutations (FTD-GRN)

Mutations in progranulin cause tau-negative frontotemporal dementia linked to chromosome 17

Protein Kinase CK-1 Inhibitors As New Potential Drugs for Amyotrophic Lateral Sclerosis

Clinical Spectrum of Amyotrophic Lateral Sclerosis (ALS). Cold Spring Harb

State of play in amyotrophic lateral sclerosis genetics

Amyotrophic lateral sclerosis

Improving clinical trial outcomes in amyotrophic lateral sclerosis

A Study of BIIB067 When Initiated in Clinically Presymptomatic Adults with a Confirmed Superoxide Dismutase 1 Mutation

Study to Assess the Safety, Tolerability, Pharmacokinetics, and Effect on Disease Progression of BIIB078 Administered to Previously Treated Adults C9ORF72-Associated Amyotrophic Lateral Sclerosis (ALS). Available online

Sarcoma: Properties, Self-Assembly and Correlation with Neurodegenerative Diseases. Molecules

Safety, Pharmacokinetics and Pharmacodynamics of ION363 in Amyotrophic Lateral Sclerosis Participants with Fused in Sarcoma Mutations (FUS-ALS). Available online

Ageing as a risk factor for neurodegenerative disease

Alzheimer's disease prevention: From risk factors to early intervention

Meta-analysis of modifiable risk factors for Alzheimer's disease

Obstructive sleep apnea, cognition and Alzheimer's disease: A systematic review integrating three decades of multidisciplinary research

Baseline subjective memory complaints associate with increased risk of incident dementia: The PREADVISE trial

REM sleep behaviour disorder

Alzheimer's disease: Definition, natural history, and diagnostic criteria

Ethical Implications of Alzheimer's Disease Prediction in Asymptomatic Individuals through Artificial Intelligence

Roadmap for Stroke: Challenging the Role of the Neuronal Extracellular Matrix